ImmuPharma Shares Jump as FDA Meeting Date Set for P140 Clinical Program
April 12 2023 - 4:02AM
Dow Jones News
By Kyle Morris
Shares in ImmuPharma PLC jumped 16% on Wednesday after the
company said that it has received Food and Drug Administration
confirmation for a pre-investigational new drug meeting on May 16
to consider a Phase 2/3 adaptive trial study protocol for its
late-stage P140 clinical program in patients with chronic
idiopathic demyelinating polyneuropathy.
The company said that a new investigational new drug submission
is required as this will be the first time that P140 is to be
studied in humans for the indication of CIDP.
Shares at 0716 GMT were up 0.35 pence at 2.50 pence.
Write to Kyle Morris at kyle.morris@dowjones.com
(END) Dow Jones Newswires
April 12, 2023 03:47 ET (07:47 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Immupharma (LSE:IMM)
Historical Stock Chart
From Oct 2024 to Nov 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Nov 2023 to Nov 2024
